| Characteristics | Community-Based Care (n = 2314) | Hospital-Based Care (n = 12,733) | P Value* |
|---|---|---|---|
| Age (years), mean (SD) | 38.5 (9.2) | 38.1 (9.1) | <.05 |
| Male sex | 1685 (72.8) | 9215 (72.4) | NS |
| Race/ethnicity | |||
| White | 828 (35.8) | 3459 (27.2) | <.01 |
| African American/Caribbean | 1028 (44.4) | 6270 (49.2) | |
| Hispanic | 386 (16.7) | 2727 (21.4) | |
| Other | 72 (3.1) | 277 (2.2) | |
| HIV risk factor | |||
| Heterosexual transmission | 995 (43.0) | 4487 (35.2) | <.01 |
| MSM | 975 (42.1) | 5094 (40.0) | |
| IDU | 288 (12.4) | 2589 (20.3) | |
| Other | 37 (1.6) | 197 (1.5) | |
| Initial CD4 during review period (cells/mm3), mean (SD) | 272 (238) | 277 (240) | NS |
| CD4 before ART (cells/mm3), mean (SD) | 266 (237) | 238 (201) | <.01 |
| Log10 viral load before treatment viral load, mean (SD) | 4.3 (0.9) | 4.5 (0.9) | <.01 |
| Number of outpatient visits per subject over review period, mean (SD) | 35.4 (32.4) | 32.8 (26.6) | NS |
| Type of ART initiated | |||
| PI only regimen | 1200 (51.9) | 6758 (53.1) | <.01 |
| NNRTI only regimen | 724 (31.3) | 3713 (29.2) | |
| PI and NNRTI | 139 (6.0) | 1038 (8.2) | |
| NRTI only | 146 (6.3) | 844 (6.6) | |
| Other† | 105 (4.5) | 380 (3.0) | |
| Number of days on ART (index regimen‡), mean (SD) | 632.7 (524.0) | 538.6 (473.2) | <.01 |
| Achieved sustained virologic suppression | 1646 (71.1) | 8416 (66.1) | <.01 |
| CD4 increase (cells/mm3), mean (SD) | 215 (220) | 197 (208) | <.01 |
Data are n (%) unless otherwise indicated.
↵* P values based on Student t test, Wilcoxon rank-sum test, or Pearson χ2.
↵† Regimens that included at least one non-PI/NNRTI antiretroviral medication were labeled “other,” regardless of whether a PI/NNRTI was concurrently prescribed as part of that regimen combination.
↵‡ Index regimen refers to the regimen that contributed to either sustained virologic suppression or treatment failure; for subjects with multiple occurrences of either outcome, the earliest qualifying regimen was counted as the index regimen. Treatment start and stop dates were submitted by HIVRN study sites.
ART, antiretroviral therapy; CD4, Cluster of Differentiation 4; IDU, intravenous drug use; MSM, men who have sex with men; NNRTI, non-nucleoside reverse transcriptase inhibitor; NRTI, nucleoside/nucleotide reverse transcriptase inhibitor; NS, not significant; PI, protease inhibitor; SD, standard deviation.